Impact of novel palmitoylated prolactin-eleasing peptide analogs on metabolic changes in mice with diet-induced obesity

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F17%3A00076048" target="_blank" >RIV/00023001:_____/17:00076048 - isvavai.cz</a>

Result on the web

<a href="http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0183449&type=printable" target="_blank" >http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0183449&type=printable</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1371/journal.pone.0183449" target="_blank" >10.1371/journal.pone.0183449</a>

Result language

angličtina

Original language name

Impact of novel palmitoylated prolactin-eleasing peptide analogs on metabolic changes in mice with diet-induced obesity

Original language description

Analogs of anorexigenic neuropeptides, such as prolactin-releasing peptide ( PrRP), have a potential as new anti-obesity drugs. In our previous study, palmitic acid attached to the N-erminus of PrRP enabled its central anorexigenic effects after peripheral administration. In this study, two linkers, gamma-glutamic acid at Lys(11) and a short, modified polyethylene glycol at the N-terminal Ser and/or Lys(11), were applied for the palmitoylation of PrRP31 to improve its bioavailability. These analogs had a high affinity and activation ability to the PrRP receptor GPR10 and the neuropeptide FF2 receptor, as well as short-term anorexigenic effect similar to PrRP palmitoylated at the N-terminus. Two-week treatment with analogs that were palmitoylated through linkers to Lys(11) (analogs 1 and 2), but not with analog modified both at the N-terminus and Lys(11) (analog 3) decreased body and liver weights, insulin, leptin, triglyceride, cholesterol and free fatty acid plasma levels in a mouse model of diet-induced obesity. Moreover, the expression of uncoupling protein-1 was increased in brown fat suggesting an increase in energy expenditure. In addition, treatment with analogs 1 and 2 but not analog 3 significantly decreased urinary concentrations of 1-methylnicotinamide and its oxidation products N-methyl-2-pyridone-5-carboxamide and N-methyl-4-pyridone-3-carboxamide, as shown by NMR-based metabolomics. This observation confirmed the previously reported increase in nicotinamide derivatives in obesity and type 2 diabetes mellitus and the effectiveness of analogs 1 and 2 in the treatment of these disorders.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30202 - Endocrinology and metabolism (including diabetes, hormones)

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

PLoS ONE [online]

ISSN

1932-6203

e-ISSN

—

Volume of the periodical

12

Issue of the periodical within the volume

8

Country of publishing house

US - UNITED STATES

Number of pages

23

Pages from-to

"art. no. e0183449"

UT code for WoS article

000408010000024

EID of the result in the Scopus database

—